Ionis Pharmaceuticals Inc ISI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Ionis Gets FDA Fast-Track Designation for Zilganersen in Alexander Disease
-
Alnylam's stock surges as heart drug vies with a Pfizer blockbuster
-
Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment
-
Ionis Pharmaceuticals, AstraZeneca Get FDA Approval for Rare Genetic Disease Treatment
-
Ionis, Roche Set New Pact Targeting Alzheimer's, Huntington's
Trading Information
- Previous Close Price
- $34.65
- Day Range
- $33.90–34.32
- 52-Week Range
- $22.36–56.90
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $5.41 Bil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.60
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 927
- Website
- https://www.ionispharma.com
Competitors
Valuation
|
Metric
|
ISI
|
ALNY
|
VRTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 152.12 | 26.10 |
Price/Book Value | 20.37 | — | 7.95 |
Price/Sales | 6.60 | 14.40 | 11.43 |
Price/Cash Flow | — | 66.10 | — |
Price/Earnings
ISI
ALNY
VRTX
Financial Strength
|
Metric
|
ISI
|
ALNY
|
VRTX
|
|---|---|---|---|
Quick Ratio | 6.88 | 2.78 | 2.10 |
Current Ratio | 7.61 | 3.01 | 2.52 |
Interest Coverage | −3.09 | −0.35 | −10.25 |
Quick Ratio
ISI
ALNY
VRTX
Profitability
|
Metric
|
ISI
|
ALNY
|
VRTX
|
|---|---|---|---|
Return on Assets (Normalized) | −8.75% | 5.94% | 0.42% |
Return on Equity (Normalized) | −74.23% | — | 0.55% |
Return on Invested Capital (Normalized) | −10.19% | 21.50% | −2.40% |
Return on Assets
ISI
ALNY
VRTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Dlqltxpdd | Qnnpf | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wdjjdbj | Ztwwlss | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wrgkvtkd | Rhvtby | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rltxprwgs | Ptgwrv | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Fchlwgg | Fxv | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Trwvgmhf | Jpbxc | $29.2 Bil | |||
| Moderna Inc
MRNA
| Gntsxlfjt | Fvjd | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Qpbrtvxq | Htj | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Fxrybyg | Fltrlrq | $13.2 Bil | |||
| Incyte Corp
INCY
| Pglczwx | Pygbqx | $13.0 Bil |
United States